Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

pioglitazone

- PMLiVE

AmyPore gets EU backing for Alzheimer’s and Parkinson’s therapy

Novel chimeric peptide ready to start clinical trials

- PMLiVE

Bicycles Therapeutics enters dementia discovery with venture capital fund

Ambitious UK biotech expands research scope

Brain power: fresh approaches to Alzheimer’s drug discovery

New alliances are learning from past mistakes and breaking down research barriers

- PMLiVE

Takeda’s Entyvio tops Humira in ulcerative colitis

Entyvio is important for post-merger Takeda

Biogen Idec building

Biogen, Eisai cue up BAN2401 readout in Alzheimer’s in 2022

Also considering a trial in preclinical Alzheimer’s subjects

- PMLiVE

GW Pharma’s cannabis-based medicine to be tested in dementia

Trial will be funded by Alzheimer’s Research UK

- PMLiVE

Another amyloid bust as Roche pulls crenezumab trials

Undermines amyloid hypothesis hopes. including Biogen candidate

- PMLiVE

Researchers reverse Alzheimer’s memory loss in mice

Epigenetics opens up new potential drug targets

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?

Healthcare leaders in the European Union should begin preparing for a breakthrough now

- PMLiVE

Shire bags US approval for constipation drug Motegrity

Approval is boost as Takeda takeover nears completion

- PMLiVE

Takeda secures investor backing for £46bn Shire takeover

The deal is expected to close early next year

- PMLiVE

Theranexus takes Alzheimer’s drug combo into clinic

150-subject phase 1b trial to start at eight centres in France

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links